Navigation Links
Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Date:9/18/2007

LONDON, Sept. 18 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that it has appointed Rosemary Mazanet M.D., Ph.D. as its interim Chief Executive Officer. Dr. Mazanet has significant experience in both executive and operational management in the biopharmaceutical industry.

Dr. Mazanet serves on the Board of numerous private and public pharmaceutical companies. From June 1998 to February 2004, Dr. Mazanet served as Chief Scientific Officer and a General Partner of Oracle Partners, L.P., a healthcare investment firm. As Senior Director of Clinical Research at Amgen in the early and mid 1990s, she was responsible for the submission of corporate INDs, the registration strategy and conduct of Phase I, II and III clinical trials. Dr. Mazanet also serves as an independent director at GTx, Inc. (Nasdaq: GTXI) and is a trustee at the University of Pennsylvania, School of Medicine where she received her M.D. and Ph.D. Dr. Mazanet was trained as an oncologist in the Harvard Medical System where she was also a faculty member.

Dr. Mazanet commented, "I am very excited to be involved with Morria and the development of their platform of therapeutic compounds addressing significant unmet medical needs in inflammation," said Dr. Mazanet. "We believe this new family of Multifunctional Anti-Inflammatory Drugs (MFAIDS) could bring significant benefits to patients with many different inflammatory conditions including skin, respiratory and gastrointestinal indications."

"Dr. Mazanet has a strong track record in operations, finance and regulatory affairs. We are very fortunate to have attracted the c
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...VARIOUS FINANCIAL AND RESTRUCTURING ALTERNATIVES O...irstCall/ - Angiotech Pharmaceuticals, Inc. (NASDA...utical and medical device company, today announced...ment (Ares) and New Leaf Venture Partners (New Lea...chase Agreement dated July 7, 2008. Angiotech had ...
(Date:11/21/2008).... 21 ChemDiv Inc. and Avineuro,Ph... research and development,collaboration including...t,studies in areas of neurodegenerative and psych...ed by Chemical Diversity Research Institute, ChemD... agreement provides for research funding of,clini...
(Date:11/21/2008)... 21 Intellect Neuroscie...harmaceutical company focused on development of di...nt and prevention of Alzheimer,s disease released .... Daniel Chain, its Chairman and CEO. , , ...o serve as Chairman and CEO of Intellect Neuroscie...
(Date:11/20/2008)...ersity Belfast is to become the United Kingdom,s l...r malicious ,cyber-attacks, after a funding boost ...h Council. , Almost 7m from the EPSRC will help...Centre for Secure Information Technologies (CSIT) ...tronics, Communications and Information Technology...
Breaking Biology Technology:Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners 2Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners 3Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners 4ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia 2Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 2Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 3Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 4Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO 5Queen's 'secures' £25m for UK's cyber-safety 2
...d online where Internet users play their favorite ... a character, play the character, and interact wit...se online personas to buy and wear or carry for r...g up in many venues. , ,The users are so wrapped u...r description of the phenomenon than online! , ,Wh...
...nge in the world, and we have to do something majo...inefficiencies can be attributed to transportation...s (48 percent). The breakdown was calculated by th...ics published in 2003. , ,I was told that by G.P....r the United States to survive is to keep pushing ...
...etion of an audit into state information technolog...oned another costly IT project. , ,According to a ...ate Department of Workforce Development has deci...s supposed to track unemployment claims. The syste...rprise Services, or EnABLES, was supposed to repla...
... can tell his fellow travelers a thing or two abou...rd Venture Partners as an executive-in-residence ...nces , as senior vice president of corporate devel...en toiling in Silicon Valley California for the pa...etween home and work. , ,By about 1,500 miles. , ...
Other Biology Technology:Inline intellectual property raises legal issues 2Inline intellectual property raises legal issues 3Inline intellectual property raises legal issues 4Energy conservation might take us farther than renewable fuels 2Energy conservation might take us farther than renewable fuels 3Energy conservation might take us farther than renewable fuels 4Energy conservation might take us farther than renewable fuels 5Energy conservation might take us farther than renewable fuels 6State of Wisconsin dumps another tech project 2Biotech executive books a career flight that's closer to home 2Biotech executive books a career flight that's closer to home 3
(Date:11/20/2008)...ecord Revenue Growth from Operations in Third Quar...FirstCall/ -- bioMETRX, Inc. (OTC Bulletin Board: ...r recognition products, today announced its financ...08. , , -- Revenues for the third quarter w...r second quarter revenues of $100,000. , , ...
(Date:11/20/2008)... Inc., (NMS), an Austin-based startup cofounded by...Health Science Center at Houston (UTHSC-Houston), ... and other medications, has received a record $3.5... Emerging Technology Fund (ETF). , NMS was one o...h were announced by Texas Gov. Rick Perry on Tuesd...
(Date:11/20/2008)...,s immune system hates strangers. When its securit..., This is the problem when people with type 1 di...he islet cells from a donor pancreas produce robus...rmitting independence from insulin therapy. Howeve...rking islets. , A person who has the transplant ...
(Date:11/19/2008)...time of birth, mouse ovaries are essentially a bag...al follicles are forming. This key time in ovarian... and follicles and instigates evelopment of a coho...sult is oocyte demise, yet oocytes are also essent...y to follicular formation and oocyte survival have...
Breaking Biology News(10 mins):bioMETRX, Inc. Highlights 3rd Quarter 2008 Financial Results 2Texas invests record $3.5 million in startup cofounded by UT's Mauro Ferrari 2New technique eliminates toxic drugs in islet transplant in diabetic mice 2December 2008 highlights from Biology of Reproduction 2Physician to Implant the CATANIA 28TM 29 Coronary Stent System With Polyzene 28R 29 F to Treat Chronic Total Occlusion During Live Case at the Paris C 8029 1Physician to Implant the CATANIA 28TM 29 Coronary Stent System With Polyzene 28R 29 F to Treat Chronic Total Occlusion During Live Case at the Paris C 8029 2Physician to Implant the CATANIA 28TM 29 Coronary Stent System With Polyzene 28R 29 F to Treat Chronic Total Occlusion During Live Case at the Paris C 8029 3Getting help for depression and anxiety has significant long term benefits 26938 1Sweat it out 3A UH study examines ability of sweat patches to monitor bone loss 5162 1Sweat it out 3A UH study examines ability of sweat patches to monitor bone loss 5162 2Case Western Reserve University project ties soil conservation and river management together 5161 1Case Western Reserve University project ties soil conservation and river management together 5161 2
...Thailand, will be hosting a scientific seminar in ...alaria Research: Outcomes and Perspectives" attend...ng talks and debates on a variety of topics relate...d from immunity to socio-economics. , As the Shok...nd, which borders Burma, celebrates its twentieth ...
...e of Medicine of Yeshiva University have received ...ute to study tumor "microenvironments" --where tum...hemicals in ways that all too often encourage canc...process known as metastasis. , With the new NCI g...structural biology at Einstein and the principal i...
...rising capacity for repair, researchers report in ...ed by Cell Press. The novel insight into the brain...linical implications for the treatment of brain da...ers found that mice whose brains were severely dam... one region just after birth showed substantial me...
...nitrogen at a surprisingly hot 92 degrees Celsius,... lineages of organisms capable of nitrogen fixatio...day,s plants and animals rely on to fix nitrogen. ...sue of Science supports the notion that the gene n... converting nitrogen gas, that,s unusable by life,...
Other Biology News:Twenty Years of Malaria Research: Outcomes and Perspectives 2World's smallest cancer detection device 2Neural stem cells lend the brain a surprising capacity for self-repair 2Microbe fixes nitrogen at a blistering 92 C 2Microbe fixes nitrogen at a blistering 92 C 3
Cell Proliferation Kit, For 100 slides. Immunocytochemistry.Sample types: suitable for in vivo and in vitro tissue labeling.Recommended cell number: 10 6-107 cells/ml.2-3 h post-labeling (labeling 1
Laminin beta-2 (C4)
Anti-MD-2 (IN) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C
VMAT 2 (N-19)
Biology Products: